# Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06819215/  
OnCo record `nct06819215` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT06819215 as recruiting, last updated 2025-02-11. Enrolment is 188 planned participants, an estimate. Interventions: VB15010. Primary measures include The number of subjects with adverse events/serious adverse events; The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06819215
- Phase: 1/2
- Setting: Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Preliminary Efficacy of VB15010 Tablets In Patients With Advanced Solid Tumors
- Sponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

## Sources

- ClinicalTrials.gov NCT06819215: https://clinicaltrials.gov/study/NCT06819215

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [VB15010](https://onco.cc/drugs/vb15010/)

---
JSON: https://onco.cc/api/v1/entities/nct06819215.json